Rajiv Jalan1, Francesco De Chiara1, Vairappan Balasubramaniyan1, Fausto Andreola1, Varun Khetan1, Massimo Malago2, Massimo Pinzani3, Rajeshwar P Mookerjee4, Krista Rombouts5. 1. Liver Failure Group, Institute for Liver & Digestive Health, University College of London, Royal Free, London, UK. 2. Division of Surgery, University College London, Royal Free, London, UK. 3. Regenerative Medicine & Fibrosis Group, Institute for Liver & Digestive Health, University College London, Royal Free, London, UK. 4. Liver Failure Group, Institute for Liver & Digestive Health, University College of London, Royal Free, London, UK. Electronic address: r.mookerjee@ucl.ac.uk. 5. Regenerative Medicine & Fibrosis Group, Institute for Liver & Digestive Health, University College London, Royal Free, London, UK. Electronic address: k.rombouts@ucl.ac.uk.
Abstract
BACKGROUND & AIMS: Hepatic stellate cells (HSCs) are vital to hepatocellular function and the liver response to injury. They share a phenotypic homology with astrocytes that are central in the pathogenesis of hepatic encephalopathy, a condition in which hyperammonemia plays a pathogenic role. This study tested the hypothesis that ammonia modulates human HSC activation in vitro and in vivo, and evaluated whether ammonia lowering, by using l-ornithine phenylacetate (OP), modifies HSC activation in vivo and reduces portal pressure in a bile duct ligation (BDL) model. METHODS: Primary human HSCs were isolated and cultured. Proliferation (BrdU), metabolic activity (MTS), morphology (transmission electron, light and immunofluorescence microscopy), HSC activation markers, ability to contract, changes in oxidative status (ROS) and endoplasmic reticulum (ER) were evaluated to identify effects of ammonia challenge (50 μM, 100 μM, 300 μM) over 24-72 h. Changes in plasma ammonia levels, markers of HSC activation, portal pressure and hepatic eNOS activity were quantified in hyperammonemic BDL animals, and after OP treatment. RESULTS: Pathophysiological ammonia concentrations caused significant and reversible changes in cell proliferation, metabolic activity and activation markers of hHSC in vitro. Ammonia also induced significant alterations in cellular morphology, characterised by cytoplasmic vacuolisation, ER enlargement, ROS production, hHSC contraction and changes in pro-inflammatory gene expression together with HSC-related activation markers such as α-SMA, myosin IIa, IIb, and PDGF-Rβ. Treatment with OP significantly reduced plasma ammonia (BDL 199.1 μmol/L±43.65 vs. BDL+OP 149.27 μmol/L±51.1, p<0.05) and portal pressure (BDL 14±0.6 vs. BDL+OP 11±0.3 mmHg, p<0.01), which was associated with increased eNOS activity and abrogation of HSC activation markers. CONCLUSIONS: The results show for the first time that ammonia produces deleterious morphological and functional effects on HSCs in vitro. Targeting ammonia with the ammonia lowering drug OP reduces portal pressure and deactivates hHSC in vivo, highlighting the opportunity for evaluating ammonia lowering as a potential therapy in cirrhotic patients with portal hypertension.
BACKGROUND & AIMS: Hepatic stellate cells (HSCs) are vital to hepatocellular function and the liver response to injury. They share a phenotypic homology with astrocytes that are central in the pathogenesis of hepatic encephalopathy, a condition in which hyperammonemia plays a pathogenic role. This study tested the hypothesis that ammonia modulates humanHSC activation in vitro and in vivo, and evaluated whether ammonia lowering, by using l-ornithine phenylacetate (OP), modifies HSC activation in vivo and reduces portal pressure in a bile duct ligation (BDL) model. METHODS: Primary human HSCs were isolated and cultured. Proliferation (BrdU), metabolic activity (MTS), morphology (transmission electron, light and immunofluorescence microscopy), HSC activation markers, ability to contract, changes in oxidative status (ROS) and endoplasmic reticulum (ER) were evaluated to identify effects of ammonia challenge (50 μM, 100 μM, 300 μM) over 24-72 h. Changes in plasma ammonia levels, markers of HSC activation, portal pressure and hepatic eNOS activity were quantified in hyperammonemic BDL animals, and after OP treatment. RESULTS: Pathophysiological ammonia concentrations caused significant and reversible changes in cell proliferation, metabolic activity and activation markers of hHSC in vitro. Ammonia also induced significant alterations in cellular morphology, characterised by cytoplasmic vacuolisation, ER enlargement, ROS production, hHSC contraction and changes in pro-inflammatory gene expression together with HSC-related activation markers such as α-SMA, myosin IIa, IIb, and PDGF-Rβ. Treatment with OP significantly reduced plasma ammonia (BDL 199.1 μmol/L±43.65 vs. BDL+OP 149.27 μmol/L±51.1, p<0.05) and portal pressure (BDL 14±0.6 vs. BDL+OP 11±0.3 mmHg, p<0.01), which was associated with increased eNOS activity and abrogation of HSC activation markers. CONCLUSIONS: The results show for the first time that ammonia produces deleterious morphological and functional effects on HSCs in vitro. Targeting ammonia with the ammonia lowering drug OP reduces portal pressure and deactivates hHSC in vivo, highlighting the opportunity for evaluating ammonia lowering as a potential therapy in cirrhotic patients with portal hypertension.
Authors: Zoltan V Varga; Katalin Erdelyi; Janos Paloczi; Resat Cinar; Zsuzsanna K Zsengeller; Tony Jourdan; Csaba Matyas; Balazs Tamas Nemeth; Adrien Guillot; Xiaogang Xiang; Adam Mehal; György Haskó; Isaac E Stillman; Seymour Rosen; Bin Gao; George Kunos; Pal Pacher Journal: Hepatology Date: 2018-10 Impact factor: 17.425
Authors: Sandesh C S Nagamani; Saima Ali; Rima Izem; Deborah Schady; Prakash Masand; Benjamin L Shneider; Daniel H Leung; Lindsay C Burrage Journal: Mol Genet Metab Date: 2021-04-08 Impact factor: 4.204
Authors: Virginia Gutiérrez-de-Juan; Sergio López de Davalillo; David Fernández-Ramos; Lucía Barbier-Torres; Imanol Zubiete-Franco; Pablo Fernández-Tussy; Jorge Simon; Fernando Lopitz-Otsoa; Javier de Las Heras; Paula Iruzubieta; María Teresa Arias-Loste; Erica Villa; Javier Crespo; Raúl Andrade; M Isabel Lucena; Marta Varela-Rey; Shelly C Lu; José M Mato; Teresa Cardoso Delgado; María-Luz Martínez-Chantar Journal: PLoS One Date: 2017-03-20 Impact factor: 3.240
Authors: Francesca Zanieri; Ana Levi; David Montefusco; Lisa Longato; Francesco De Chiara; Luca Frenguelli; Sara Omenetti; Fausto Andreola; Tu Vinh Luong; Veronica Massey; Juan Caballeria; Constantino Fondevila; Sriram S Shanmugavelandy; Todd Fox; Giuseppe Mazza; Josepmaria Argemi; Ramon Bataller; Lauren Ashley Cowart; Mark Kester; Massimo Pinzani; Krista Rombouts Journal: Cells Date: 2020-05-16 Impact factor: 6.600